Events

1st July 2009 Over 75 doctors from the UAE attended Continuous Medical Education Seminar (CME) organized by Eastern Biotech & Life Sciences on “Cervical Cancer & STIs- Cutting Edge Technologies & Management Strategies”   Dr. Marco Baccant Executive Director of Dubai Biotechnology & Research Park, Dubai, UAE Cervical cancer is the second most common cancer among the women worldwide, causing 250,000 deaths annually (WHO report). According to a report published by Ministry of Health in 2005, about 43 women die in the UAE alone due to cervical cancer each year. The number has multiplied significantly in the last couple of years. The most recent report suggests, 10 women die each day in the Middle East among the estimated 650 deaths worldwide. HPV (Human Papilloma Virus) is the cause of 99.7% of cervical cancer cases and HPV Genotypes 16 and 18 causes approximately 70% of cervical cancers worldwide. Thus it is important to clearly identify those women at increased risk of developing cervical cancer at an early stage. The seminar and the workshop were held at Rotana Towers Hotel, Dubai on 1st July 2009, organized by Eastern Biotech & Life Sciences, supported and sponsored by Dubiotech, Glaxo smithcline & Life Cell International. Ministry of Health, United Arab Emirates acknowledged and rewarded the event with 4.0 CME credit points. Dr. Marco Baccanti, Executive Director of DuBiotech, Dubai presided over the seminar. The primary objective of the workshop is to raise awareness of cervical cancer among the clinicians and how the latest technologies can be helpful to detect the deadly disease at an early stage, thus prevent the fatalities of such conditions. Speakers suggested that the combination of liquid based cytology used for pap smear with the Digene Hybrid capture 2 techniques for HPV genotyping would be beneficial to detect the infection and the disease at an early stage. “HPV infection is very common in sexually active men and women. It is usually transient and results only in mild cytological abnormalities. About 80 % of women between 19 and 30 years clear this infection within months or years, but in some cases persistent infection of high risk HPV can lead to the development of cervical cancer” said Dr. Rihab Awad from Mitera Clinic, DHCC, Dubai, during her speech on “The Need of Clinical Education to Raise an Awareness of HPV Screening and Cervical Cancer Prevention”. Dr. Sanjida Ahmed Research Director for Eastern Biotech & Life Sciences discussed about various Sexually Transmitted Infections (STI), diagnostic tools available to detect them and the cutting edge technologies recently been utilized and marketed by various companies around the world to diagnose these infections. She mentioned that Hybrid Capture 2 DNA Test could be advantageous for the patients in terms of reducing their physical, mental and financial load. Detecting HPV means better understanding of the risk of cervical cancer was the major focus of Dr. Dinesh Gupta from National Clinical Reference Laboratory, New Delhi India. He spoke on “Opportunistic Screening for Cervical Precancer Lesions” and informed why the combination screening is vital for prevention and detection of cervical cancer. According to Dr. Gupta, combined screening with liquid based cytology and hybrid capture2 HPV DNA test would identify who’s at risk for high-grade disease and cancer and reduce missed disease caused by false-negative Pap Smear. HPV DNA test is the only FDA approved test to detect 13 high risk HPVs associated with virtually all cervical cancer, he added. HPV vaccine now available is a new powerful weapon to fight against cervical cancer, Dr. Rima Abu Omar from Al Zahra Hospital, Sharjah, emphasized. She also stated that Vaccine is the Primary Protection against Cervical Cancer and women as young as 9 years should be vaccinated before they approach the puberty. About Eastern Biotech & Life Sciences: Eastern Biotech & Life Sciences is a UAE based Biotechnology Company under the Dubai Biotechnology and Research Park, DUBIOTECH, Dubai. The company has a vision to prevent morbidity and mortality among individuals and families with or at risk of genetic, congenital, and/or familial disorders. Eastern Biotech provides quality screening, education and family-centered comprehensive services for the Middle Eastern people. The company offers the most recent technologies like Hybrid capture technique combined with Liquid based cytology for detection of HPV and detection of other STIs from a single swab sample. Veiw Events

Dr. Rihab Khalil Awad, MBCHB, MRCOG Mitera Clinic, DHCC, Dubai, UAE Dr. Sanjida Ahmed Eastern Biotech & Life Sciences Dubai, UAE Dr. Rima Abuomar, MBBS, MRCOG, OBGYN Jordanian Board Al Zahra Hospital Dubai, UAE Dr. Dinesh Gupta, National Clinical Reference Laboratory New Delhi, India

April 2009

Police are to create a state-of-the-art forensic facility to match the world’s best, the emirate’s chief of police said yesterday. Lt Gen Dahi Khalfan Tamim said that Century Laboratory, now under construction, would use the latest technology and expertise.

Veiw Events

April 2009

Presentation by Eastern Biotech at the PABME Conference
Junaid Faruq, Marketing Director of Eastern Biotech & Life Sciences presented at the conference of Pharmaceuticals and Biotechnology Middle East (PABME), one of the Life Sciences Division events of IIR Middle East, which includes the highly successful Arab Health in its portfolio.

PABME is the largest gathering of Pharma and biotech related specialists in the Middle East - designed to be a global platform for industry leaders to converge, network and develop new business, PABME is the must attend event for any professional within the pharma and biotech industry. Now also with the inclusion of the Pharma section of Arab Health, this is the largest event of its kind in the region.

Junaid Faruq spoke about the “Management of Inherited and Infectious Diseases” in the Current Trends in Pharmaceuticals and Biotechnology session chaired by Dr. Marco Bccanti, Executive Director, Dubai Biotechnology & Research Park (DuBiotech).

Members of Eastern Biotech including Dr. Faruq M Badiuddin, Dr. Sanjida Ahmed and Pankaj Sohaney were present in the occasion.

Veiw Events

18^th February, 2009

Recent Advances in Genetic Testing

Topic: Syndrome Based Diagnostics: A Single Test using DNA Macrochip to Detect Multiple
Pathogens in Eye & Brain Infection

Dr. Ravi Kumar, MBBS, PhD (NeuroChemistry)

• Chairman and Managing Director, XCyton Diagnostics Limited, India.
  
• General Secretary, Association of Biotech Led Enterprises, India
  

17^th February, 2009

Recent Advances in Genetic Testing

Topic: Syndrome Based Diagnostics: A Single Test using DNA Macrochip to Detect Multiple
Pathogens in Eye & Brain Infection

Dr. Ravi Kumar, MBBS, PhD (NeuroChemistry)

• Chairman and Managing Director, XCyton Diagnostics Limited, India.
  
• General Secretary, Association of Biotech Led Enterprises, India
  

Topic: Risk Reduction of Genetic Disorders by Premarital, Prenatal & Neonatal Screening

Dr. Sanjida Ahmed

• PhD, Cell Biology
  
• Director, Research, Eastern Biotech & Life Sciences, Dubai, UAE

November 2009

Recent Advances in Genetic Testing
Genetic Testing has now reached a stage where it is becoming increasingly applicable for rapid and accurate diagnosis of common infective / congenital disorders as well as the basis for prediction of cancers and lifestyle diseases.

These advances are opening up new avenues for the clinicians to offer their patients innovative tools to achieve optimum health. 'Advanced Genetic Testing in the prediction & diagnosis of disease' conference is aiming to introduce a broad spectrum of new diagnostic tools available to clinicians in an attempt to incorporate there use in routine practices.

The conference is proudly organized by Eastern Biotech & Life Sciences; a Genetic Biotechnological company based out of DuBiotech, Dubai and will be held in Dubai (UAE) on the 27th of November 2008. It is supported by the Ministry of Health, United Arab Emirates and has been formally granted 3.0 CME credit points.

	Dr. Ghazi Omar Tadmouri Assistant Director, Centre for Arab Genomic Studies, UAE	Dr. I.C. Verma, FRCP (Lond.), FAMS(India), FAAP (USA) Senior Consultant and Head, Department of Genetic Medicine, Sir Ganga Ram Hospital, New Delhi	Dr. Ravi Kumar, MBBS, PhD (NeuroChemistry), IISC, Bangalore Chairman and Managing Director, XCyton Diagnostics Limited, India.

The conference aims to promote knowledge exchange on using diagnostic testing as a tool for supporting the advancement of genetic innovation throughout the world. The conference will bring together approximately 75 key industry figureheads and stakeholders throughout the GCC headlined by 4 internationally acclaimed genetic specialists presenting their knowledge and ideas fostering genetic and biotechnological innovation specifically: